Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUKELSO vs ABELCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.
Advanced renal cell carcinoma,Progressive neuroendocrine tumors of pancreatic origin,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis,Advanced neuroendocrine tumors of gastrointestinal or lung origin
Invasive fungal infections refractory to amphotericin B deoxycholate or in patients intolerant to that formulation,Aspergillosis,Candidiasis,Cryptococcosis,Blastomycosis,Histoplasmosis,Coccidioidomycosis,Zygomycosis,Fungal sinusitis,Empiric therapy in febrile neutropenic patients (off-label),Visceral leishmaniasis (off-label)
400 mg orally twice daily with food.
5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Terminal elimination half-life is approximately 120–180 hours (mean ~153 h) in adults with normal renal and hepatic function. This long half-life reflects slow redistribution from tissues and supports once-daily dosing after a loading regimen.
Primarily metabolized by CYP3A4
Amphotericin B is not significantly metabolized in humans; it is eliminated primarily via biliary excretion with negligible renal metabolism.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Renal excretion is minimal (<1% unchanged drug); the primary route of elimination is via the hepatobiliary system, with the majority of the dose recovered in feces as unchanged drug and metabolites. Biliary/fecal elimination accounts for >90% of clearance.
High protein binding, approximately 99.8%, primarily to albumin and alpha-1-acid glycoprotein.
More than 99% bound to plasma proteins, primarily to albumin and lipoproteins (e.g., LDL and HDL).
Volume of distribution ~0.15 L/kg (range 0.12–0.18 L/kg), indicating limited extravascular distribution, predominantly confined to plasma and extracellular fluid.
Volume of distribution is approximately 0.5–1.0 L/kg, indicating extensive tissue distribution (e.g., liver, spleen, lung, kidney) with limited penetration into cerebrospinal fluid and vitreous humor.
Oral bioavailability ~85%; unaffected by food.
Not applicable; only administered intravenously. Oral bioavailability is negligible (less than 5%) due to poor gastrointestinal absorption and degradation in the GI tract.
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg twice daily; GFR <30 m L/min: 200 mg once daily; hemodialysis: 200 mg three times weekly after dialysis.
No dosage adjustment required, but renal function should be monitored; consider dose adjustment if Cr Cl < 30 m L/min or if significant nephrotoxicity occurs (e.g., doubling of serum creatinine).
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg twice daily; Child-Pugh C: 200 mg once daily.
No specific adjustment; use with caution in severe hepatic impairment.
Body weight 10-20 kg: 200 mg twice daily; 20-40 kg: 300 mg twice daily; ≥40 kg: 400 mg twice daily.
Same dosing as adults (5 mg/kg/day IV); safety and efficacy established.
No specific dose adjustment based on age alone; monitor renal function and adjust per renal guidelines.
No specific adjustment, but monitor renal function and electrolyte balance due to higher risk of toxicity.
No FDA black box warning.
WARNING: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections in patients intolerant to conventional amphotericin B deoxycholate or whose infection is refractory to that formulation. Not interchangeable with other amphotericin B products. Verify correct product prior to administration. Administer by intravenous infusion only.
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions,Renal impairment,Metabolic effects (hyperglycemia, hyperlipidemia),Interstitial lung disease,Hemorrhagic events,Wound healing complications,Immunosuppression,Increased risk of thrombosis
Nephrotoxicity: monitor renal function closely; may cause azotemia, hypokalemia, hypomagnesemia,Hypersensitivity reactions: anaphylaxis, bronchospasm, flushing, hypotension,Infusion-related reactions: fever, chills, rigors, headache, nausea, vomiting,Cardiotoxicity: arrhythmias, cardiac arrest (especially during rapid infusion),Hepatotoxicity: elevated liver enzymes, bilirubin,Hematologic toxicity: anemia, thrombocytopenia, leukopenia,Electrolyte disturbances: hypokalemia, hypomagnesemia, hyponatremia,Pulmonary toxicity: dyspnea, respiratory failure (rare),Prior to infusion: premedicate with antipyretics, antihistamines, and corticosteroids to reduce infusion reactions
Hypersensitivity to everolimus or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation,Concurrent administration with other nephrotoxic drugs (e.g., cyclosporine, tacrolimus, aminoglycosides) unless benefit outweighs risk,Severe pre-existing renal impairment (relative contraindication; use only if no alternative)
Avoid grapefruit and grapefruit juice; may increase drug levels. Take with or without food, but high-fat meals may increase absorption. Avoid alcohol due to hepatotoxicity risk.
No known food interactions. Maintain adequate hydration.
First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and third trimesters: Use only if maternal benefit outweighs fetal risk; may cause fetal growth restriction or oligohydramnios in off-label experience. No adequate human data.
Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. However, systemic fungal infections pose significant maternal and fetal risk if untreated. Use only if clearly needed.
No human data on milk excretion or infant effects. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression), advise against breastfeeding during treatment and for 2 weeks after last dose.
It is not known whether amphotericin B is excreted in human milk. Because many drugs are excreted in human milk and due to the potential for adverse effects in nursing infants, the decision to discontinue nursing or discontinue the drug should be made, taking into account the importance of the drug to the mother. M/P ratio unknown.
No established dose adjustment in pregnancy. Consider reduced dosing if increased clearance occurs (second trimester). Monitor drug levels if available; otherwise, adjust based on clinical response and toxicity.
No specific dosing adjustments are recommended for pregnancy. However, given the potential for renal impairment and electrolyte disturbances, close monitoring is warranted. Dose adjustments are primarily based on renal function, which may be altered in pregnancy.
Monitor for QT prolongation, electrolyte abnormalities, and hepatotoxicity. Adjust dose in renal impairment (Cr Cl <30 m L/min). Avoid use with strong CYP3A4 inhibitors or inducers. Note potential for phototoxicity; advise sun avoidance.
Monitor renal function and electrolytes closely; premedicate with diphenhydramine and acetaminophen to reduce infusion-related reactions; do not mix with saline or other electrolytes; administer via in-line filter (5 micron) only; ensure adequate hydration to prevent nephrotoxicity.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 1 month after last dose.,Report symptoms like irregular heartbeat, fainting, severe nausea/vomiting, or yellowing of skin/eyes immediately.,Use sunscreen and protective clothing; avoid sun exposure, even through glass.
This medication is given intravenously and may cause fever, chills, or rigors during infusion.,Report any breathing difficulty, chest pain, or severe reaction immediately.,You may receive pre-medications to reduce side effects.,Stay well hydrated unless instructed otherwise.,Blood tests will be required to monitor kidney function and electrolytes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUKELSO vs ABELCET, answered by our medical review team.
AUKELSO is a Topical Antifungal that works by Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.. ABELCET is a Polyene antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUKELSO and ABELCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUKELSO is: 400 mg orally twice daily with food.. The standard adult dose of ABELCET is: 5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUKELSO and ABELCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUKELSO is classified as Category C. First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and . ABELCET is classified as Category C. Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. How. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.